CYTOKINES AND STEM CELL TRANSPLANTATION FOR REFRACTORY LYMPHOMAS
CYTOKINES AND STEM CELL TRANSPLANTATION FOR REFRACTORY LYMPHOMAS
批准号:
3752506
负责人:
D L LONGO
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Hodgkin's disease cis platinum compound colony stimulating factor combination cancer therapy combination chemotherapy combination therapy cytokine etoposide hematopoietic stem cells hematopoietic tissue transplantation human subject human therapy evaluation human tissue ifosfamide interleukin 1 neoplasm /cancer relapse /recurrence neoplasm /cancer remission /regression nonHodgkin's lymphoma
中文摘要
现代化疗治愈了大多数霍奇金病患者
和中度非霍奇金淋巴瘤。 然而,标准剂量
化疗很少能治愈那些不能达到预期效果的患者。
诱导化疗完全缓解或初始完全缓解
缓解期少于12个月。 高剂量化疗和
自体骨髓移植已经能够实现更长的
在某些患者中持续完全缓解。有明确
需要提高骨髓和外周血
在这些患者中使用清髓性方案后,
治疗。 在这项研究中,霍奇金病和非霍奇金病患者
联合化疗可以使淋巴瘤缩小。 那些患者
达到完全缓解或90%部分缓解,接受高-
ICE剂量化疗(异环磷酰胺、卡铂、依托泊苷)
方案.作为干细胞的来源,骨髓和外周血
将用于 在采集外周血和骨髓之前,
患者将接受IL-1 β和G-CSF。 高剂量后
化疗和这些干细胞,患者将接受额外的G-CSF。
目前,只有6名患者登记。 一名患者没有
因淋巴瘤累及骨髓而入组; 2例患者
死于治疗相关毒性,3例患者达到
完全缓解 两名霍奇金病患者仍处于CR状态,
3+和2+年。 1例非霍奇金淋巴瘤患者CR后复发
持续了两年,目前正在接受治疗。
英文摘要
Modern chemotherapy cures the majority of patients with Hodgkin's disease
and intermediate grade non-Hodgkin's lymphomas. However, standard dose
chemotherapy is rarely curative for patients who fail to achieve a
complete remission to induction chemotherapy or whose initial complete
remission lasts less than 12 months. High-dose chemotherapy and
autologous bone marrow transplantation have been able to achieve longer
lasting complete remissions in some of these patients. There is a clear
need for improving the rates at which bone marrow and peripheral blood
counts recover following the myeloablative regimens used in these
treatments. In this study, patients with Hodgkin's and non-Hodgkin's
lymphoma are debulked with combination chemotherapy. Those patients
achieving a complete remission, or 90% partial remission, receive high-
dose chemotherapy with the ICE (ifosfamide, carboplatin, etoposide)
regimen. As a source of stem cells, both bone marrow and peripheral blood
will be used. Prior to harvesting peripheral blood and bone marrow,
patients will receive IL-1beta and G-CSF. Following high-dose
chemotherapy and these stem cells, patients will receive additional G-CSF.
Still only six patients have been registered. One patient was not
enrolled because of bone marrow involvement with lymphoma; two patients
died from treatment-related toxicity and three patients achieved a
complete remission. Two patients with Hodgkin's disease remain in CR at
3+ and 2+ years. One patient with non-Hodgkin's lymphoma relapsed from CR
lasting 2 years and is currently undergoing therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF B-CELL LYMPHOMAS WITH ANTI-B4-BLOCKED RICIN IMMUNOCONJUGATE
-
批准号:3838244
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
MOPP VS RADIOTHERAPY FOR EARLY STAGE HODGKIN'S DISEASE
-
批准号:3838209
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
5FU, LEUCOVORIN, AZT & PERSANTINE FOR MELANOMA, RENAL, AND COLORECTAL CANCER
-
批准号:3838218
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
TREATMENT OF STAGE I DIFFUSE AGGRESSIVE LYMPHOMAS
-
批准号:3853324
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
PROMACE-CYTABOM TREATMENT FOR ANGIOCENTRIC IMMUNOPROLIFERATIVE LESIONS
-
批准号:3874549
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
MOPP/ABVD FOLLOWED BY RADIOTHERAPY FOR MASSIVE MEDIASTINAL HODGKIN'S DISEASE
-
批准号:3896350
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
MOPP VERSUS RADIOTHERAPY FOR EARLY STAGE HODGKIN'S DISEASE
-
批准号:3752488
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
TREATMENT OF B-CELL LYMPHOMAS WITH ANTI-B4-BLOCKED RICIN IMMUNOCONJUGATE
-
批准号:3752511
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
PROMACE-CYTABOM TREATMENT FOR ANGIOCENTRIC IMMUNOPROLIFERATIVE LESIONS
-
批准号:3752490
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
DOSE INTENSE MOPP FOR PATIENTS WITH POOR PROGNOSIS HODGKIN'S DISEASE
-
批准号:3874546
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
CYTOKINES AND STEM CELL TRANSPLANTATION FOR REFRACTORY LYMPHOMAS
-
批准号:3838237
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
SHORT COURSE PROMACE-CYTABOM FOR STAGES II-IV DIFFUSE AGGRESSIVE LYMPHOMA
-
批准号:3838207
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
PROMACE-CYTABOM TREATMENT FOR ANGIOCENTRIC IMMUNOPROLIFERATIVE LESIONS
-
批准号:3838211
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
GENETIC REGULATION OF THE IMMUNE RESPONSE
-
批准号:4692161
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
TREATMENT OF STAGE I DIFFUSE AGGRESSIVE LYMPHOMAS
-
批准号:3752491
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
OBSERVATION VS. INTENSIVE CHEMOTHERAPY FOR INDOLENT LYMPHOMA
-
批准号:3874548
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
PHASE I TRIAL OF ANTI-CD3 MONOCLONAL ANTIBODIES IN PATIENTS WITH ADVANCED CANCER
-
批准号:3874543
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
SHORT COURSE PROMACE-CYTABOM FOR STAGES II-IV DIFFUSE AGGRESSIVE LYMPHOMA
-
批准号:3874545
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
5FU, LEUCOVORIN, AZT & PERSANTINE FOR MELANOMA, RENAL, AND COLORECTAL CANCER
-
批准号:3874554
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位:
OBSERVATION VS. INTENSIVE CHEMOTHERAPY FOR INDOLENT LYMPHOMA
-
批准号:3853322
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:D L LONGO
-
依托单位: